Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarker technology, is extending its reach in the United States with the inauguration of a new office in Cambridge, Massachusetts. This strategic move places IAG in close proximity to major biotechnology and pharmaceutical companies in the Boston area, enhancing its ability to forge stronger partnerships and offer direct support for clinical trials within the region.
The Cambridge location is set to bolster IAG’s work across various therapeutic fields, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic disorders. It aims to facilitate closer collaboration with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-focused development programs. As part of this expansion, IAG intends to generate local job opportunities in clinical imaging operations, data science, regulatory support, and business development over the coming 12 to 24 months.
With this new office, IAG will provide comprehensive imaging services, encompassing clinical trial design consultation, optimization of imaging protocols, centralized image analysis, and delivery of data that meets regulatory standards. The company anticipates that its presence in the Boston life-sciences ecosystem will enhance collaboration with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers.
Globally, IAG is engaged in supporting clinical trials throughout North America, Europe, and the Asia-Pacific region. It collaborates with pharmaceutical, biotechnology, and medtech companies, as well as CROs, on multi-center studies. IAG’s global operations are structured to deliver standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). It supports pharmaceutical, biotechnology, and medical technology companies by providing imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials, covering areas such as oncology, inflammatory diseases, musculoskeletal conditions, cardiometabolic issues, and rare disease indications. For more information, IAG can be contacted through their website or via email.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.